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ABSTRACT  
 
Aims 
There is a need for more evidence on the ‘real-world’ effectiveness of commonly used aids to 
smoking cessation from population-level studies. This study assessed the association between 
abstinence and use of different smoking cessation treatments after adjusting for key potential 
confounding factors. 
 
Design 
Cross-sectional data from aggregated monthly waves of a household survey: the Smoking Toolkit 
Study. 
 
Setting 
England. 
 
Participants 
10,335 adults who smoked within the previous 12 months and made at least one quit attempt 
during that time. 
 
Measurements 
Participants were classified according to their use of cessation aids in their most recent quit 
attempt: (1) medication (nicotine replacement therapy, bupropion, or varenicline) in combination 
with specialist behavioural support delivered by a National Health Service Stop Smoking Service; 
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(2) medication provided by the prescribing health care professional without specialist behavioural 
support; (3) nicotine replacement therapy (NRT) bought over-the-counter; (4) none of these. The 
main outcome measure was self-reported abstinence up to the time of the survey, adjusted for 
key potential confounders including tobacco dependence. 
 
Findings 
Compared with smokers using none of the cessation aids, the adjusted odds of remaining 
abstinent up to the time of the survey were 3.25 (95%CI=2.05-5.15) greater in users of prescription 
medication in combination with specialist behavioural support, 1.61 (95%CI=1.33-1.94) greater in 
users of prescription medication combined with brief advice, and 0.96 (95%CI=0.81-1.13) in users 
of NRT bought over-the-counter.  
 
Conclusions 
After adjusting for major confounding variables such as tobacco dependence, smokers in England 
who use a combination of behavioural support and pharmacotherapy in their quit attempts have 
almost three times the odds of success than those who use neither pharmacotherapy or 
behavioural support. Smokers who buy nicotine replacement therapy over the counter with no 
behavioural support have similar odds of success as stopping as those who stop without any aid. 
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INTRODUCTION  
The World Health Organization (WHO) estimates that smoking kills nearly six million people each 
year.1 Every year that someone continues to smoke after early middle age loses them 3 months of 
life expectancy.2 It is therefore important that every quit attempt has the best possible chance of 
success. There is strong evidence from multiple randomized controlled trials that behavioural 
support and several medications improve the success of quit attempts.3-9 However, population-
based studies about the effectiveness of smoking cessation treatments in the "real world" have 
produced mixed results. This is particularly important because we are now in the implementation 
phase of Article 14 of the WHO Framework Convention on Tobacco Control which mandates 
signatory countries to promote smoking cessation in their populations10,11; so real-world evidence 
on effectiveness of treatment to aid cessation will have global impact. Real-world studies using 
observational designs cannot provide the same degree of confidence in causal associations as 
randomised trials because of the possibility of residual confounding but without them the 
generalizability of the randomised trial evidence will always be called into question. Thus both 
types of study are essential. 
 
Some "real world" studies have reported a lower chance of successful quitting in smokers who 
used nicotine replacement therapy (NRT) or bupropion than in smokers who tried to quit without 
medication.12-15 However, these studies did not adequately control for important confounding 
factors, most notably the fact that smokers who use these medications are more dependent on 
cigarettes.16-19 Of the few studies that have attempted to control for such confounding, one US 
study20 found a lower chance of successful quitting in users of NRT and bupropion compared with 
non-users of smoking cessation treatment whereas two multinational studies18,21 found higher 
chances of quitting in users of NRT, bupropion, or varenicline. However, these did not investigate 
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the effect of behavioural support provided or distinguish between NRT bought over-the-counter 
versus obtained from a health care professional. This leaves a critical gap in the literature.  
 
The current study is the first with adequate power to assess the real-world effectiveness of 
medication for smoking cessation combined with behavioural support in comparison with unaided 
quitting using population-based survey data while adjusting for key potential confounding factors. 
In addition to controlling for dependence, the current study adjusted for a number of other factors 
that have been associated with both successful quitting and choice of treatment including age, 
sex, social grade, and previous quit attempts.20,22-26 Importantly, this study also distinguishes 
between the provision of specialist behavioural support and brief advice. England is a country with 
the most extensive and comprehensive coverage of behavioural support and medications in the 
world, and the highest rate of use of these aids to cessation.27 Therefore it is probably the only 
country where a population level study of this kind could be undertaken. Every smoker has ready 
access to behavioural support and medication that is either free or available at nominal charge. In 
addition, all the forms of NRT are available to be purchased over-the-counter. As these aids have 
been available for at least 10 years, the market is mature and any associations are not likely to 
reflect the fact that the interventions are novel. This makes England a unique environment for the 
assessment of the real-world effectiveness of different quitting methods.  
 
METHODS  
We used data from the "Smoking Toolkit Study": an ongoing research program designed to 
provide information about smoking cessation and factors that promote or inhibit it at a population 
level.28,29 Each month a new sample of approximately 1,800 people aged 16 and over completes a 
face-to-face computer-assisted survey, of whom approximately 450 are smokers. The methods 
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have been described in full elsewhere and have been shown to result in figures for key variables 
such as smoking prevalence that are nationally representative.28  
 
Study population 
For the current study, we used aggregated data from respondents to the survey in the period from 
November 2006 (the start of the survey) to May 2012 (the latest wave of the survey for which data 
were available), who smoked cigarettes (including hand-rolled) or any other tobacco product (e.g., 
pipe or cigar) daily or occasionally at the time of the survey or during the preceding 12 months. 
We included those who made at least one quit attempt in the preceding 12 months, assessed by 
asking: "How many serious attempts to stop smoking have you made in the last 12 months? By 
serious attempt I mean you decided that you would try to make sure you never smoked again. 
Please include any attempt that you are currently making and please include any successful 
attempt made within the last year." We also asked how long ago the most recent quit attempt 
started and categorised respondents into those who started their quit attempt in the last week or 
up to 6 months ago and those who started their quit attempt more than 6 months ago.  
 
Measurement of effect: use of smoking cessation treatments  
The use of smoking cessation treatments was assessed only for the most recent quit attempt and 
included: (1) NRT on prescription (NRT Rx), bupropion, or varenicline in combination with 
specialist behaviour support (i.e., one-to-one or group behavioural support delivered by a National 
Health Service (NHS) Stop Smoking Service); (2) NRT Rx, bupropion, or varenicline in combination 
with brief advice (delivered by the prescribing health care professional); (3) NRT bought over-the-
counter; (4) none of these. 
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Measurement of outcome: self-reported non-smoking  
Our primary outcome was self-reported non-smoking up to the time of the survey. Respondents 
were asked: "How long did your most recent serious quit attempt last before you went back to 
smoking?". Those responding "I am still not smoking" were defined as non-smokers. Previous 
research has shown that self-reported abstinence in surveys of this kind is not subject to the kind 
of biases observed in clinical trials where there is social pressure to claim abstinence.30,31    
 
Measurement of potential confounders  
We measured variables potentially associated with the use of smoking cessation treatments and 
that may also have an effect on the outcome. These potential confounders were chosen a priori. 
The most important factor was cigarette dependence for which we used two questions. First, time 
spent with urges to smoke was assessed by asking: "How much of the time have you felt the urge 
to smoke in the past 24 hours? Not at all (coded 1), a little of  the time (2), some of the time (3), a 
lot of the time (4), almost all of the time (5), all of  the time (6)". Second, strength of urges to 
smoke was measured by asking "In general, how strong have the urges to smoke been?": slight (1), 
moderate (2), strong (3), very strong (4), extremely strong (5). This question was coded "0" for 
smokers who responded "not at all" to the previous question. These two ratings have been found 
in this population to be a better measure of dependence (more closely associated with relapse 
following a quit attempt) than other measures.32 Demographic characteristics we took into 
account were age, sex, and social grade (measured on an ordinal scale: AB = managerial and 
professional occupations, C1 = intermediate occupations, C2 = small employers and own account 
workers, D = lower supervisory and technical occupations, and E = semi-routine and routine 
occupations, never workers, and long-term unemployed). Furthermore, we measured the number 
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of quit attempts in the last year prior to the one in question, and time since the quit attempt in 
question was initiated.  
 
Data analyses 
Simple associations between potential confounders and use of the smoking cessation treatments 
were assessed with ANOVA for continuous variables and Pearson's χ2 for categorical variables. 
Tukey's post-hoc procedure was used for multiple comparisons of the two measures of tobacco 
dependence. 
 
Our measure of dependence (strength of urges to smoke) assumed that the score relative to other 
smokers would stay the same from pre- to post-quitting. Thus a measure taken after the quit 
attempt would reflect, relative to other smokers in the same position (i.e., having stopped or 
failed to stop), what it would have been prior to it. The absolute score would reduce between 
these two occasions but this reduction would not be affected substantially by the method of 
quitting. If a method of quitting reduced strength of urges to smoke more than another method, 
this would tend to underestimate the effectiveness of that intervention because the smokers 
using this method would appear to be less dependent. If it increased the strength of urges it would 
overestimate the method’s effectiveness by making it seem that the smokers were more 
dependent than they actually were. To test for this bias we examined in an ANCOVA whether the 
difference in strength of urges to smoke in smokers versus quitters varied as a function of the 
method of quitting, adjusting for the time since the quit attempt started. Although the power to 
detect such an interaction in the population would be relatively low, our interest is only in 
whether the interaction exists in this sample since it is that which could artificially inflate or 
deflate our estimate of the association between quitting method and success. 
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For our primary analysis, we used a multiple logistic regression model in which we regressed the 
outcome measure (self-reported non-smoking compared with smoking) on the effect measure 
(use of each of the three smoking cessation treatments compared with no use of such 
treatments), adjusted for the above mentioned confounders and year of the survey. We also 
included two interaction terms: (1) between time since last quit attempt and time spent with 
urges, and (2) between time since last quit attempt and strength of urges to smoke. These 
interaction terms were used to account for the fact that urges to smoke following the quit attempt 
will be influenced by whether the respondent is currently abstinent and the duration of 
abstinence. However, we also ran this model after excluding the two interaction terms in a 
sensitivity analysis.  
 
The sample size in our study provided 99% power to detect an odds ratio of 3.0 for the comparison 
of medication on prescription + specialist behavioural support versus no treatment, and 94% 
power to detect an odds ratio of 1.5 for the comparison of medication on prescription + brief 
advice versus no treatment (effect sizes estimated from randomised controlled trials).      
 
In addition to the model from the primary analysis ("fully adjusted model"), we constructed a 
simple model including only the effect measure ("unadjusted model") and a model that included 
the effect measure, year of the survey and all confounders except for the two measures of 
tobacco dependence and their interaction terms ("partially adjusted model") to show the extent 
of confounding effects of tobacco dependence.  
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In a sensitivity analysis we excluded respondents who had used telephone counselling for smoking 
cessation during their most recent quit attempt; very few smokers in England use this form of 
treatment so it is not possible to assess its association with abstinence. In the primary analysis 
these smokers were conservatively counted in the "no treatment" group unless they had also used 
medication whereas in the sensitivity analysis they were excluded from the analysis. 
 
All analyses were repeated in the two subsamples of respondents who had started their most 
recent quit attempt less versus more than 6 months ago in order to assess the occurrence of 
differential recall bias. It has been suggested that smokers who try to stop unaided forget failed 
quit attempts more quickly than those who use treatment.16 In the presence of such bias the long-
term effectiveness of smoking cessation treatments would be underestimated. However, a 
positive association would provide evidence for lasting treatment effects of a kind that have been 
questioned by previous researchers.12 
 
All analyses were performed with complete cases. Respondents with missing data on one or more 
of the variables were excluded (5.5% of the initial sample). 
  
RESULTS 
The study population consisted of 10,335 respondents; 8,932 (86.4%) who smoked and 1,403 
(13.6%) who were abstinent at the time of the survey. The unadjusted abstinence rates were 
19.1% (N=39) for users of medication on prescription in combination with specialist behavioural 
support, 15.2% (N=259) for users of prescription medication combined with brief advice, 10.2% 
(N=322) for users of NRT bought over-the-counter, and 14.8% (N=783) for those using none of 
these treatments. A subgroup of 6,510 respondents (63.0% of the full study population) had 
  Page 12 
 
started their last quit attempt less than 6 months ago and 3,825 (37.0%) had started their last quit 
attempt more than 6 months ago. Demographic and smoking-related characteristics of the full 
sample are shown in Table 1. The characteristics of the two subsamples of smokers who had 
started their last quit attempt more versus less than 6 months ago were similar (not shown in the 
table).  
  
A total of 1,910 respondents (18.5%) had used some form of prescription medication during their 
most recent quit attempt. Among these respondents, the majority had used NRT Rx (58.1%, 
N=1,110), followed by varenicline (28.2%, N=538), and bupropion (10.9%, N=208). The remaining 
2.8% (N=54) of respondents had used some combination of these medications.  
 
The use of treatments was associated with age, sex, time since last quit attempt started and the 
two measures of dependence (time spent with and strength of urges to smoke) (Table 2). The use 
of treatments also differed according to social grade. The post-hoc comparisons showed more 
time spent with urges to smoke and stronger urges to smoke in the three groups that used 
smoking cessation medication compared with the group that did not use medication (all p<0.001). 
   
Table 3 shows the differences in strength of urges to smoke in smokers versus non-smokers, 
stratified by method of quitting. As would be expected strengths of urges to smoke were higher in 
smokers than in quitters and in those smokers using more intensive methods of quitting. However, 
the mean differences in strength of urges between smokers and quitters were not different across 
the methods of quitting: The interaction term between smoking status (smokers versus quitters) 
and method of quitting in the ANCOVA of the strength of urges adjusted for the time since quit 
attempt started was not statistically significant (p=0.44). 
  Page 13 
 
  
There was evidence of preferential recall of quit attempts made 6+ months ago if medication on 
prescription or behavioural support was used but not if NRT bought over-the-counter was used. 
Thus, reported rates of use of medication in combination with specialist behavioural support and 
use of prescription medication combined with brief advice were higher in respondents who had 
started their most recent quit attempt more than 6 months ago compared with the subsample 
who had started less than 6 months ago (2.5% vs. 1.7% for medication combined with specialist 
behavioural support and 17.7% vs. 15.8% for medication combined with brief advice, p<0.01). 
Reported use of NRT over-the-counter was similar within the subsamples (29.9% vs. 30.5%), 
whereas the reported rate of no treatment use was lower within the subsample of respondents 
who had started their most recent quit attempt more than 6 months ago than in the subsample 
who had started less than 6 months ago (49.9% vs. 52.1%, p<0.01).  
 
Table 4 shows that in the full sample, the fully adjusted odds (model 4) of non-smoking in users of 
medication on prescription in combination with specialist behavioural support were 3.25 times 
higher compared with the no-treatment group. The odds were 2.02 times higher compared with 
the group that used prescription medication combined with brief advice (not shown in the table). 
In the latter group, the odds were 1.61 times higher compared with the no-treatment group. The 
use of NRT bought over-the-counter was not associated with abstinence (OR=0.96). These odds 
ratios were similar to the odds ratios of the fully adjusted model excluding the two interaction 
terms (model 3). The relative magnitudes of the odds ratios from the fully adjusted model (model 
4) with the unadjusted model (model 1) and the partially adjusted model 2 show the large 
confounding effects of cigarette dependence.  
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A total of 114 respondents (1.1%) reported having used telephone counselling during their most 
recent quit attempt. The percentage of telephone counselling users was higher in the group that 
used medication on prescription in combination with NHS counselling (7.4%) than in the other two 
treatment groups and the no-treatment group (percentages between 0.6-1.2%). Excluding these 
respondents from the primary analysis increased the association between non-smoking and use of 
medication on prescription in combination with specialist behavioural support (fully adjusted 
OR=3.51, 95%CI=2.19-5.61), but did not change the association with the other two treatments. 
 
In smokers who started their quit attempt more than 6 months ago, the fully adjusted odds of 
non-smoking in users of medication on prescription in combination with specialist behavioural 
support were 2.32 (95%CI=1.15-4.67) times higher compared with the no treatment group, 
whereas the odds were not statistically significantly higher in users of prescription medication 
combined with brief advice (OR=1.26, 95%CI=0.91-1.76).  
  
DISCUSSION 
Use of prescription medication in combination with specialised behavioural support during 
attempts to quit smoking was associated with the success of such attempts as was use of 
prescription medication with limited support. No such association was detected for NRT bought 
over-the-counter.  
 
Our adjusted odds ratio of 1.61 in users of prescription medication combined with brief advice 
compared with non-users of treatment was similar to that from meta-analyses of randomized 
placebo-controlled trials 6,7,8. Our estimated effectiveness of adding behavioural support to 
medication (OR=2.02) was slightly higher than would be expected from a meta-analysis performed 
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for the US guidelines.33 It is noteworthy that adjusting for dependence made a substantial 
difference to these odds ratios and emphasises the importance in this kind of study of adequately 
controlling for this very substantial confounder. 
 
Our findings conflicted with those from a meta-analysis of the effectiveness of NRT bought over-
the-counter.34 Preferential recall of quit attempts using this method does not appear to explain 
this finding. We cannot rule out an effect of unmeasured confounding factors but it should be 
noted that this ought to have undermined the observed effects of behavioural support and 
medication on prescription, yet we were able to detect these effects. If NRT over-the-counter has 
become ineffective in England, this represents a considerable financial and opportunity cost for 
smokers and steps need to be taken urgently to address this.  
 
As noted in the introduction, findings from similar studies to ours without adequate adjustment 
for cigarette dependence12-15,20 cannot be relied upon. This rules out most cross-sectional surveys 
because the most commonly used measure of cigarette dependence uses number of cigarettes 
smoked and time to first cigarette of the day. When smokers relapse they tend to do so with 
reduced consumption which can lead to a false estimation of prior dependence. We avoided this 
by using a validated measure involving ratings of current urges to smoke and statistically adjust for 
whether this was during normal smoking or a period of abstinence.32 However, our findings with 
regard to medication are consistent with many prospective real-world studies.18,21,25,35-38  
 
Studies of the kind reported here do not in themselves allow causal inferences of the association 
between treatment and outcome but they are essential to examine how far the findings from 
randomized trials generalize to population samples. We reduced the risk of confounding further 
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than any previous study by adjusting for cigarette dependence, age, sex, social grade, and previous 
quit attempts. However, residual confounding may have occurred as not all factors associated with 
self-selection of treatment were measured in our survey, such as co-morbidity39 or psychological 
distress40. Motivation to quit may also be positively associated with both use of treatment and 
success. However, population studies have generally not found an association between motivation 
to quit and success of quit attempts.41 Finally, our survey is limited by the fact that it does not 
contain data on medication adherence. 
 
The value of ratings of strength of urges to smoke as a measure of dependence in cross-sectional 
research would have been reduced if different methods of stopping had been found differentially 
to be linked to lower or higher levels of urges in abstinent smokers. For example, a method of 
stopping that led to a relatively higher reduction in urges might underestimate the effectiveness of 
that method by making it seem that those using it were less dependent. However, we did not find 
evidence in this population data set that urges to smoke in smokers versus quitters differed as a 
function of method. It is very unlikely, therefore, that our dependence measure led to substantial 
overestimation or underestimation of the effectiveness of the different methods. 
  
Reliance on recall is inevitable in population studies of this kind and even in prospective studies it 
is an issue unless one stimulates quit attempts. In our study, with the quit attempt having 
occurred up to 12 months ago, the scope for recall bias is significant.20,42 This would tend to 
reduce the ability to detect an effect and does not undermine the finding of a significant benefit of 
behavioural support plus medication. The effect sizes for medication with specialist behavioural 
support or with brief advice were lower in smokers who started their quit attempt more than 6 
months ago than in smokers who started their quit attempt less than 6 ago. This finding may be a 
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result of differential recall bias. We found some evidence in our study that the use of prescription 
medication during a quit attempt, especially when combined with specialised behavioural support, 
was recalled better than no use of treatment during a quit attempt (we did not find evidence of 
recall bias in usage of NRT bought over-the-counter). Our finding may, however, also be a result of 
reduced long-term effectiveness of prescription medication when prescribed with brief advice 
only.    
 
To maximize statistical power, we combined the prescription of NRT, bupropion, and varenicline in 
our study. It would be useful to compare these medications with each other once sufficient 
samples have been accumulated. 
 
We defined our measure of outcome as whether or not participants had remained abstinent from 
the quit date to the time of the survey. Another approach would have been to assess how long 
participants reported having been abstinent since their quit date, even if they had relapsed by the 
time of the survey. We decided not to use this measure because of added noise and potential bias 
with smokers recalling the point at which they had relapsed, bearing in mind that they make 
different interpretations on what constituted relapse (e.g. was it the first lapse, or return to daily 
smoking?). It was not feasible in our large population study to biochemically validate self-reported 
non-smoking. This would be a serious limitation in randomized controlled trials because of the 
possibility of differential likelihood of falsely claiming abstinence by participants in the active 
treatment.43 However, in population surveys the misreporting rate is low.30,31   
 
A major strength of our study is the use of a very large, representative sample of the English 
population – sufficient to permit detection of an effect of behavioural support despite its low 
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frequency. Our study included all smokers aged 16 years or older including those who smoke less 
than 10 cigarettes per day, a group that constitutes one third of current smokers.44 Furthermore, 
we used aggregated data from monthly surveys over a period of 5.5 years and therefore 
eliminated potential bias from the fact that the rate of attempts to quit in smokers is different at 
different times of the year.    
 
Conclusions and recommendations  
This is the first evidence from a population sample of the real-world effectiveness of the 
combination of behavioural support and stop-smoking medication as recommended by the US 
Department of Health and Human Services guidelines33 once adequate adjustment is made for 
confounding particularly by cigarette dependence. We also confirmed the effectiveness of stop-
smoking medication provided with minimal support by health professionals, at least in the short 
term. Importantly, we did not detect an effect of NRT bought over-the-counter. 
 
Health care professionals should know that smokers who seek treatment differ from smokers who 
try to quit unaided in that they have more difficulties quitting. In those smokers, a combination of 
evidence-based medication combined with expert behavioural support is recommended. More 
research is urgently needed on real world effectiveness of nicotine replacement therapy bought 
over the counter. 
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Table 1: Sample characteristics (N=10,335)  
Age, mean (SD)  39.5 (15.6) 
Female sex 54.0 (5,576) 
Social grade 
 AB 
 C1 
 C2 
 D 
 E 
 
10.7 (1,105) 
22.9 (2,371) 
22.7 (2,351) 
18.8 (1,945) 
24.8 (2,563) 
Current non-smokers 13.6 (1,403) 
Time since last quit attempt started  
 <=1 to 26 weeks   
 26 to 52 weeks   
 
63.0 (6,510) 
37.0 (3,825) 
Number of quit attempts in the past year 
 1   
 2   
 3   
 4 or more   
 
64.5 (6,661) 
21.9 (2,264) 
7.6 (783) 
6.1 (627) 
Use of smoking cessation treatments 
Medication on prescription + specialist behavioural support 
Medication on prescription + brief advice  
NRT bought over-the-counter   
None of the above   
 
2.0 (204) 
16.5 (1,706) 
30.3 (3,128) 
51.3 (5,297) 
Time spent with urges to smoke, mean (SD) 3.0 (1.3) 
Strength of urges to smoke, mean (SD) 2.0 (1.2) 
Figures are presented as percentage (N), unless stated otherwise. Medication on prescription included nicotine 
replacement therapy (NRT), varenicline or bupropion. Time spent with urges to smoke: 1 (not at all) to 6 (all the time). 
Strength of urges to smoke: 0 (no urges) to 5 (extremely strong urges).  
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Table 2: Associations between characteristics of the sample and use of smoking cessation treatments  
Variable Medication on 
prescription + specialist 
behavioural support 
(N=204) 
Medication on 
prescription + brief 
advice 
(N=1,706) 
NRT bought over-the-
counter 
(N=3,128) 
None of the other 
(N=5,297) 
P 
Age, mean (SD)  46.5 (14.1) 43.3 (14.8) 40.8 (15.0) 37.2 (15.9) *** 
Sex  
 Male 
 Female 
 
34.3 (70) 
65.7 (134) 
 
42.4 (724) 
57.6 (982) 
 
45.4 (1,424) 
54.5 (1,704) 
 
48.0 (2,541) 
52.0 (2,756) 
 
*** 
Social grade 
 AB 
 C1 
 C2 
 D 
 E 
 
 13.7 (28) 
21.1 (43) 
25.0 (51) 
14.2 (29) 
26.0 (53) 
 
9.4 (160) 
20.1 (343) 
23.4 (399) 
19.5 (332) 
27.7 (472) 
 
11.1 (348) 
23.4 (732) 
21.5 (671) 
18.0 (564) 
26.0 (813) 
 
10.7 (569) 
23.7 (1,253) 
23.2 (1,230) 
19.3 (1,020) 
23.1 (1,225) 
 
** 
Time since quit attempt started  
 <=1 to 26 weeks   
 26 to 52 weeks   
 
53.4 (109) 
45.6 (95) 
 
60.3 (1,028) 
39.7 (678) 
 
63.4 (1,984) 
36.6 (1,144) 
 
64.0 (3,389) 
36.0 (1,908) 
 
** 
Number of quit attempts in the past year 
 1   
 2   
 3   
 4 or more   
 
64.7 (132) 
22.1 (45) 
6.9 (14) 
6.4 (13) 
 
67.6 (1,153) 
20.9 (356) 
6.0 (103) 
5.5 (94) 
 
63.0 (1,970) 
22.5 (703) 
8.5 (266) 
6.0 (189) 
 
64.3 (3,406) 
21.9 (1,160) 
7.6 (400) 
6.2 (331) 
n.s. 
Time spent with urges to smoke, mean (SD) 3.3 (1.3) 3.2 (1.4) 3.2 (1.2) 2.8 (1.2) *** 
Strength of urges to smoke, mean (SD) 2.3 (1.3) 2.2 (1.2) 2.2 (1.1) 1.8 (1.1) *** 
Figures are presented as percentage (N), unless stated otherwise. Medication on prescription included nicotine replacement therapy (NRT), varenicline or bupropion. Time spent 
with urges to smoke: 1 (not at all) to 6 (all the time). Strength of urges to smoke: 0 (no urges) to 5 (extremely strong urges). *p<0.05, **p<0.01, ***p<0.001, n.s. = not statistically 
significant (p>=0.05). 
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Table 3: Differences in unadjusted measurements of strength of urges to smoke in smokers versus non-smokers, stratified by method of quitting 
Method of quitting  
 
(N) 
Mean (SD) strength 
of urges to smoke 
in smokers 
  
 
(N) 
Mean (SD) strength 
of urges to smoke in 
non-smokers 
 Mean difference 
(95% CI) in strength 
of urges to smoke 
Medication on prescription + specialist behavioural support (165) 2.59 (1.10)  (39) 1.31 (1.66)  1.29 (0.73-1.85) 
Medication on prescription + brief advice  (1,447) 2.43 (1.05)  (259) 1.05 (1.31)  1.38 (1.21-1.55) 
NRT bought over-the-counter   (2,806) 2.33 (1.03)  (322) 1.06 (1.24)  1.28 (1.14-1.42) 
None of the above   (4,514) 2.02 (1.03)  (783) 0.76 (1.16)  1.26 (1.17-1.35) 
Medication on prescription included nicotine replacement therapy (NRT), varenicline or bupropion. Strength of urges to smoke: 0 (no urges) to 5 (extremely strong urges). The 
mean difference in strength of urges to smoke was not different across the methods of quitting (p=0.44 for the interaction term between smoking status (smokers vs. quitters) and 
method of quitting adjusted for the time since the quit attempt started).  
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Table 4: Unadjusted and adjusted odds of self-reported non-smoking in the full sample and in the two subsamples of respondents who started 
their quit attempt less/more than 6 months ago  
Smoking cessation treatment   OR (95%CI) 
Model 1 Model 2 Model 3 Model 4 
Full sample (N=10,335)     
Medication on prescription + specialist behavioural support (N=204) 
Medication on prescription + brief advice (N=1,706) 
NRT bought over-the-counter (N=3,128)  
None of the above (reference) (N=5,297) 
1.36 (0.95-1.95) 
1.03 (0.89-1.20) 
0.66 (0.58-0.76) 
1 
1.47 (1.02-2.11) 
1.02 (0.87-1.19) 
0.63 (0.55-0.74) 
1 
2.97 (1.93-4.59) 
1.59 (1.32-1.91) 
0.95 (0.81-1.12) 
1 
3.25 (2.05-5.15) 
1.61 (1.33-1.94) 
0.96 (0.81-1.13) 
1 
Subsample: quit attempt started <6 months (N=6,510)     
Medication on prescription + specialist behavioural support (N=109) 
Medication on prescription + brief advice (N=1,028) 
NRT bought over-the-counter (N=1,984)  
None of the above (reference) (N=3,389) 
1.45 (0.90-2.34) 
1.21 (1.00-1.46) 
0.60 (0.60-0.84) 
1 
1.83 (1.12-3.01) 
1.20 (0.98-1.46) 
0.68 (0.57-0.82) 
1 
3.80 (2.17-6.67) 
1.78 (1.42-2.23) 
0.97 (0.80-1.00) 
1 
4.35 (2.35-8.03) 
1.78 (1.42-2.24) 
1.00 (0.82-1.22) 
1 
Subsample: quit attempt started >6 months (N=3,825)     
Medication on prescription + specialist behavioural support (N=95) 
Medication on prescription + brief advice (N=678) 
NRT bought over-the-counter (N=1,144)  
None of the above (reference) (N=1,908) 
1.27 (0.74-2.17) 
0.78 (0.60-1.01) 
0.59 (0.46-0.75) 
1 
1.14 (0.66-1.98) 
0.74 (0.57-0.98) 
0.56 (0.44-0.71) 
1 
2.32 (1.15-4.67) 
1.26 (0.91-1.76) 
0.87 (0.66-1.15) 
1 
2.32 (1.15-4.67) 
1.26 (0.91-1.76) 
0.87 (0.66-1.15) 
1 
Model 1 = unadjusted. Model 2 = adjusted for age, sex, social grade, number of quit attempts in the last year prior to the one in question, time since last quit attempt started, and 
year of the survey. Model 3 =  adjusted for the variables from model 2 and time spent with urges to smoke, strength of urges to smoke. Model 4 = adjusted for the variables from 
model 2 and the interaction terms time since last quit attempt started * time spent with urges, time since last quit attempt started * strength of urges to smoke. Medication on 
prescription included nicotine replacement therapy (NRT), varenicline or bupropion. OR = odds ratio, 95%CI = 95% confidence interval around OR. 
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Supplementary Table E1: Percentage (95%CI) non-smokers in each treatment condition stratified 
by strength of urges to smoke in the full sample (N=10,335) 
Smoking cessation treatment  Strength of urges to 
smoke‡ 
Non-smoker 
Medication on prescription + specialist behavioural support  Low 
(N=117) 
25.6 (17.7-33.6) 
High 
(N=87) 
10.3 (3.9-16.7) 
Medication on prescription + brief advice Low 
(N=1,030) 
21.1 (18.6-23.6) 
High 
(N=676) 
6.2 (4.4-8.0) 
NRT bought over-the-counter  Low 
(N=2,033) 
13.8 (12.3-15.3) 
 High 
(N=1,095) 
3.8 (2.7-5.0) 
None of the above  Low 
(N=4,011) 
17.7 (16.5-18.6) 
 High 
(N=1,286) 
5.8 (4.5-7.0) 
‡Split by median: low strength of urges to smoke = scores 0 to 2, high = scores 3 to 5. 95%CI = 95% confidence interval. 
  
 
